CION Ameerpet
Understanding Your Report · Reviewed by CION Oncologists · NABH Accredited
Type 2 Endometrial Cancer — A Different Disease, Not a Worse Version
If your report names serous, clear cell or carcinosarcoma, you have one of the non-endometrioid types — and the most useful thing to understand is that these are not simply more advanced versions of the common cancer. They arise by a different route, in different women, and they behave differently. They are not driven by oestrogen, they have no hyperplasia stage before them, they are high grade by definition, and they are more likely to have spread beyond the uterus by the time they are found. That is a harder starting position, stated plainly — and it changes what treatment is offered rather than whether treatment is offered.
- Three subtypes — uterine serous, clear cell, and carcinosarcoma
- Not oestrogen-driven — often on a thin lining in an older woman, with no precancer stage
- High grade by definition — not graded 1 to 3, because they are all treated as high grade
- Treated more intensively — chemotherapy is considered even for early-stage disease
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The Three Subtypes
They are grouped together because they share aggressive behaviour, but they are distinct diseases with their own characteristics.
| Subtype | What distinguishes it |
|---|---|
| Uterine serous carcinoma | The commonest of the three. Behaves like high-grade serous ovarian cancer, spreading across peritoneal surfaces, and is frequently p53-abnormal. Staging surgery typically includes omental and peritoneal assessment. See uterine serous carcinoma. |
| Clear cell carcinoma | Named for the appearance of its cells, which look clear because of their glycogen content. Uncommon, aggressive, and less well characterised than serous carcinoma simply because it is rarer. See uterine clear cell carcinoma. |
| Carcinosarcoma | Contains both carcinoma and sarcoma-like components. Once classified as a sarcoma, now understood as a carcinoma that has undergone a change in appearance, and treated as an aggressive endometrial cancer. See uterine carcinosarcoma. |
| Mixed tumours | Some tumours contain both endometrioid and non-endometrioid components. Where a serous or clear cell component is present, the tumour is generally managed according to that component regardless of how much of it there is. |
| Grade 3 endometrioid | Technically Type 1, and frequently grouped with these for treatment purposes because it behaves comparably. A reminder that the dividing line is behavioural rather than absolute. See Grade 3 endometrial cancer. |
A note on uterine sarcoma. True sarcomas of the uterus — leiomyosarcoma and endometrial stromal sarcoma — arise from muscle or connective tissue rather than the lining, and are a separate disease from all of the above. They are frequently confused with carcinosarcoma. See uterine sarcoma.
Did You Know? Uterine serous carcinoma has more in common with high-grade serous ovarian cancer than with the endometrioid cancer that shares its organ. It spreads across the peritoneal surfaces of the abdomen in the same pattern, it is frequently p53-abnormal in the same way, and it is treated with a similar surgical and chemotherapy approach. That is why staging surgery for serous carcinoma often includes assessment of the omentum and peritoneum — steps that would be unnecessary for a low-grade endometrioid tumour. If you have read about ovarian cancer and found it more familiar than what you have read about endometrial cancer, there is a real reason for that. See ovarian cancer. Sources: World Health Organization classification of tumours of female reproductive organs; The Cancer Genome Atlas integrated genomic characterisation of endometrial carcinoma; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESGO–ESTRO–ESP guidelines.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Why These Behave So Differently
Four differences from the common type, and each has a practical consequence.
- No oestrogen dependence. These tumours are not produced by unopposed oestrogen, so the usual risk-factor profile does not apply. A slim woman with regular cycles, children and no diabetes can develop one — which is precisely why any postmenopausal bleeding is investigated regardless of how low-risk someone appears.
- No precancer stage. There is no hyperplasia phase to catch beforehand, so the prevention window that exists for Type 1 disease simply is not there. Detection depends entirely on the tumour causing bleeding and that bleeding being reported.
- A tendency to spread within the abdomen. Serous carcinoma in particular seeds across peritoneal surfaces, which is why disease can be found beyond the uterus even when the tumour within it is small — a pattern that does not occur with low-grade endometrioid cancer.
- Frequently p53-abnormal. A molecular finding associated with worse behaviour, and one which now sits inside the FIGO staging system. It is part of why these tumours are managed as high risk regardless of apparent stage. See molecular testing.
The consequence that matters most: a small Type 2 tumour is not equivalent to a small Type 1 tumour. Stage understates the situation here, which is why the histological type has been folded into the current staging system rather than left beside it.
Been Given One of These Diagnoses?
This is the group where a proper tumour board discussion matters most. Bring everything you have and we will review it as a team.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Harder Starting Position, Treated Accordingly
These cancers are treated more intensively because they need to be — and treatment is still given with the aim of cure at early stage.
What Treatment Involves
More than for the common type, and the differences are deliberate rather than cautious.
- More thorough staging surgery. Hysterectomy with removal of tubes and ovaries, plus assessment of the omentum and peritoneal surfaces and node evaluation — steps that would be unnecessary for a low-grade endometrioid tumour but reflect where these cancers spread. See hysterectomy.
- Chemotherapy considered even at early stage. The most important difference. Where an early low-grade endometrioid tumour would need nothing after surgery, chemotherapy is discussed for Type 2 disease confined to the uterus, because of the risk of spread that imaging and surgery cannot exclude. See chemotherapy.
- Radiation, often alongside. Vault brachytherapy or pelvic radiation depending on the findings, frequently combined with chemotherapy rather than as an alternative to it. See pelvic radiation.
- Molecular testing that genuinely changes options. Every tumour is tested for mismatch repair status, and a deficient result opens the immunotherapy route which has changed outcomes materially for that subgroup in advanced disease. See immunotherapy.
- Closer follow-up. Recurrence risk is higher and the pattern differs — attention extends to abdominal symptoms rather than focusing narrowly on the vaginal vault. See the follow-up schedule.
Want a Tumour Board Opinion on a Type 2 Diagnosis?
Whether the staging was complete, whether molecular testing has been done, and whether the treatment sequence is right. The opinion is free.
Four Questions Worth Asking
These are the ones that most change what happens next in this group.
“Has my tumour had full molecular testing?”
Specifically mismatch repair status and p53. Mismatch repair deficiency opens the immunotherapy route, which has produced durable responses in advanced disease and is the most significant advance in this field in years. p53 status confirms the high-risk classification. Both are performed on tissue already available, and if they have not been done that is worth resolving before treatment decisions are finalised.
“Was the staging surgery complete?”
For serous carcinoma in particular, assessment of the omentum and peritoneal surfaces matters because that is where this tumour spreads. A hysterectomy performed for what was assumed to be a low-grade endometrioid tumour, with the serous component only identified afterwards on the final pathology, may not have included those steps — and that is worth discussing openly rather than leaving unexamined.
“Has this been through a tumour board?”
At this level of risk the sequence of surgery, chemotherapy and radiation should be decided by the whole team at once rather than by each specialty in turn. A plan assembled sequentially by three separate clinicians tends to produce a worse combined result than one designed as a whole, and this is the group where that difference matters most.
“What is the plan aiming for?”
At early stage the aim is cure, and it is worth hearing that said. Treatment is more intensive here because the risk is higher, not because the situation is hopeless. Understanding the intent also lets you weigh side effects sensibly, which is a legitimate part of the conversation rather than an obstacle to it.
Talking Honestly About the Outlook
These cancers carry a less favourable outlook than endometrioid disease, and it would be dishonest to write around that. Three things belong alongside it.
- Stage still matters enormously. A serous carcinoma confined to the uterus and one that has spread through the abdomen are very different situations, and the first is treated with the aim of cure. Type is not destiny.
- Published figures predate current treatment. Five-year survival data necessarily describes women treated years ago, before molecular classification was routine and before immunotherapy was available for mismatch repair deficient disease. In this group specifically, the data lags practice more than usual.
- Molecular group can shift the picture within the type. A mismatch repair deficient serous carcinoma is in a materially different position from a p53-abnormal one when it comes to treatment options, and that distinction did not exist in older statistics at all.
- We do not publish a CION endometrial survival figure. Indian registry data for this cancer is limited and thinner still for these uncommon subtypes. We would rather say so than print a number we cannot stand behind. See survival by stage.
Why This Group Needs Everything in One Place
Surgery, chemotherapy and radiation planned together, by people who see these subtypes often enough to recognise them.
Tumour board for every diagnosis
Slides reviewed, not just the summary line
MMR / MSI testing as standard
One place for the whole pathway
Named MCh surgical oncologists
Psycho-oncology and nutrition on the team
Take The Next Step
Ask Whether the Molecular Testing Is Complete
It can change what is available to you, and it is done on tissue you have already given.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Type 2 Endometrial Cancer — Frequently Asked Questions
What is Type 2 endometrial cancer?
It is a group of non-endometrioid endometrial cancers comprising uterine serous carcinoma, clear cell carcinoma and carcinosarcoma. They differ from the common endometrioid type in several fundamental ways: they are not driven by oestrogen exposure, they typically arise on a thin atrophic lining in older postmenopausal women, they are not preceded by an endometrial hyperplasia stage, and they are regarded as high grade by definition rather than being assigned a grade of 1 to 3. They also have a greater tendency to spread beyond the uterus, including across the peritoneal surfaces of the abdomen. They are best understood as different diseases rather than as more advanced versions of the common one.
Why is chemotherapy offered even though my cancer was confined to the uterus?
Because the risk of undetected spread is materially higher with these subtypes than with endometrioid cancer, and neither imaging nor surgery can exclude it reliably. Serous carcinoma in particular seeds across peritoneal surfaces, so disease can be present beyond the uterus even when the tumour within it is small. Chemotherapy is systemic — it circulates — so it addresses that risk in a way that surgery and radiation, which treat defined areas, cannot. Where a low-grade endometrioid tumour confined to the uterus would frequently need nothing after surgery, chemotherapy is discussed for Type 2 disease at the same apparent stage. It is a deliberate difference, not excess caution.
Why is uterine serous carcinoma compared to ovarian cancer?
Because it behaves like it, and this is genuinely useful to understand. Uterine serous carcinoma has more in common with high-grade serous ovarian cancer than with the endometrioid cancer that shares its organ: it spreads across the peritoneal surfaces of the abdomen in the same pattern, it is frequently p53-abnormal in the same way, and it is treated with a comparable surgical and chemotherapy approach. This is why staging surgery for serous carcinoma often includes assessment of the omentum and peritoneum, steps that would be unnecessary for a low-grade endometrioid tumour. If material about ovarian cancer has seemed more relevant to you than material about endometrial cancer, there is a real reason.
Does a Type 2 diagnosis mean a poor outlook?
It carries a less favourable outlook than endometrioid disease and that should not be written around — but three things belong alongside it. Stage still matters enormously: a serous carcinoma confined to the uterus and one that has spread through the abdomen are very different situations, and the first is treated with the aim of cure. Published survival figures necessarily describe women treated years ago, before molecular classification was routine and before immunotherapy was available for mismatch repair deficient disease, so in this group the data lags practice more than usual. And within the type, molecular group changes what treatment options exist.
What molecular testing should I have?
Mismatch repair status and p53 at minimum, and both are performed on tumour tissue you have already provided. Mismatch repair deficiency identifies women likely to benefit from checkpoint inhibitor immunotherapy, which has produced durable responses in advanced disease and represents the most significant advance in this field in recent years — so it directly determines what is available to you. A p53-abnormal result confirms high-risk classification and is characteristic of serous carcinoma and carcinosarcoma. Under the 2023 FIGO staging system these findings feed into the stage itself rather than sitting alongside it. If testing has not been done, ask whether stored tissue can be used.
Medical disclaimer: This page explains the non-endometrioid Type 2 endometrial cancers in general terms and is reviewed by a CION oncologist, following the World Health Organization classification and current NCCN and ESGO–ESTRO–ESP guidance. It describes tumour behaviour at a population level and does not predict an outcome for any individual. Indian registry data for these uncommon subtypes is limited, and we do not publish a CION endometrial survival figure for that reason. Treatment decisions should be made with an oncology team holding your full pathology and molecular results.